New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study
- Status
- WITHDRAWN
- Phase
- PHASE2
Clinical Trials Related to Leucovorin
Related studies linked through entity extraction aliases.
HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)
- Status
- RECRUITING
- Phase
- PHASE3
Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric Cancer or Esophagogastric Junction Adenocarcinoma (Type II-III)
- Status
- UNKNOWN
- Phase
- PHASE2
FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
FOLFIRINOX vs FLOT Chemotherapy for Resectable Gastric or Esophagogastric Junction Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies
- Status
- RECRUITING
- Phase
- PHASE1
Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
- Status
- COMPLETED
- Phase
- PHASE1
mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
- Status
- RECRUITING
- Phase
- PHASE2
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
- Status
- COMPLETED
- Phase
- PHASE1
A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment
- Status
- COMPLETED
- Phase
- PHASE3